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harmful and dependent drinking and moderate
to severe depression in primary care in India:
PREMIUM study protocol for randomized
controlled trials
Vikram Patel1,2*, Benedict Weobong2,3, Abhijit Nadkarni1,2, Helen A Weiss2, Arpita Anand1, Smita Naik1, Bhargav Bhat1,
Jesina Pereira1, Ricardo Araya2, Sona Dimidjian4, Steven D Hollon5, Michael King6, Jim McCambridge2, David McDaid7,
Pratima Murthy8, Richard Velleman9, Christopher G Fairburn10 and Betty Kirkwood2Abstract
Background: The leading mental health causes of the global burden of disease are depression in women and
alcohol use disorders in men. A major hurdle to the implementation of evidence-based psychological treatments in
primary care in developing countries is the non-availability of skilled human resources. The aim of these trials is to
evaluate the effectiveness and cost-effectiveness of two psychological treatments developed for the treatment of
depression and alcohol use disorders in primary care in India.
Methods/design: This study protocol is for parallel group, randomized controlled trials (Healthy Activity Program
for moderate to severe depression, Counselling for Alcohol Problems for harmful and dependent drinking) in eight
primary health centres in Goa, India. Adult primary care attendees will be screened with the Patient Health
Questionnaire for depression and, in men only, the Alcohol Use Disorders Identification Test for drinking problems.
Screen-positive attendees will be invited to participate; men who screen positive for both disorders will be invited
to participate in the Counselling for Alcohol Problems trial. Those who consent will be allocated in a 1:1 ratio to
receive either the respective psychological treatment plus enhanced usual care or enhanced usual care only using a
computer generated allocation sequence, stratified by primary health centre and, for depression, by sex. The
enhanced usual care comprises providing primary health centre doctors with contextualized World Health
Organization guidelines and screening results. Psychological treatments will be delivered by lay counsellors, over a
maximum period of three months. Primary outcomes are severity of disorder and remission rates at three months
post-enrolment and, for the Counselling for Alcohol Problems trial, drinking and the impact of drinking on daily
lives. Secondary outcomes include severity of disorder and remission rates at 12 months, disability scores, suicidal
behaviour and economic impact, and cost-effectiveness at three and 12 months. 500 participants with depression
and 400 participants with harmful drinking will be recruited. Primary analyses will be intention-to-treat.
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Discussion: These trials may offer a new approach for the treatment of moderate-severe depression and drinking
problems in primary care that is potentially scalable as it relies on delivery by a single pool of lay counsellors.
Trial registration: Both trials are registered with the International Society for the Registration of Clinical Trials
(Healthy Activity Programme registration number ISRCTN95149997; Counselling for Alcohol Problems registration
number ISRCTN76465238).
Keywords: Alcohol use disorders, Depression, Low- and middle-income countries, Non-specialist health workers,
Psychological treatmentsBackground
Psychological treatments (PTs) are ‘talking’ treatments in
which a therapist aims to modify ways of thinking, feel-
ing, behaving and relating with others with the goal of
facilitating recovery from distressing mental phenomena.
The vast majority of people with mental disorders who
live in low- and middle-income countries (LMICs) do
not have access to any form of treatment, particularly
PTs. Two major barriers to making treatments accessible
are the lack of skilled human resources for delivering
treatments and concerns regarding the context and
generalizability of treatments developed in ‘western’ cul-
tural settings. The goal of PREMIUM, a Program for
Effective Mental Health Interventions in Under-resourced
Health Systems, is to implement a PT development and
evaluation methodology that will lead to effective PTs for
mental disorders that are culturally appropriate, feasible,
acceptable and affordable in under-resourced settings. A
core element of this methodology is a long-term vision of
ultimate scalability of treatments by emphasizing their de-
livery by the same pool of lay counsellors working in rou-
tine primary health care settings.
This methodology is being applied for the treatment
of two mental disorders affecting adults: depression and
alcohol use disorder (AUD). These two disorders have
been chosen for the following reasons. First, they are the
two leading causes of the global burden of mental disor-
ders; depression is the leading mental disorder affecting
women, AUD is the leading mental disorder affecting men
[1]. Both disorders are associated with profound adverse
social impacts on the persons affected and their fam-
ilies. Second, although effective pharmacological treat-
ments exist for the severe forms of both disorders, PTs
are recommended as first-line treatments in LMICs [2,3].
The primary target groups will be moderate to severe
depression and harmful drinking (HD). This is because
the World Health Organization (WHO) treatment guide-
lines for primary care advocate the use of brief structured
PTs for moderate to severe depression and HD [4]. Anti-
depressants are also advocated for moderate to severe
depression but these benefit only a third to half of pa-
tients with depression [5] and a recent trial of collabora-
tive care for common mental disorders in primary care inIndia observed low adherence [6]. Furthermore, PTs are
associated with lower relapse rates when compared with
antidepressant medication [7] and a recent UK trial dem-
onstrated that adding PT to routine primary care for
treatment-resistant depression greatly enhanced recovery
rates [5]. ‘Brief interventions’ are the cornerstone for
the management of HD [8]; they are as effective as
more extended interventions, can be effectively deliv-
ered in primary care and are twice as likely to reduce
drinking compared with no intervention [9-12]. Lim-
ited evidence exists in support of brief interventions
for reducing drinking in patients with more severe
forms of AUD, namely alcohol dependence (AD). How-
ever, there is some evidence that shows that brief inter-
ventions lead to reduced drinking in patients with AD
[13,14] and it is well established that rates of engage-
ment with addictions treatment services can be en-
hanced [9,13,15-17].
The vast majority of trials of PT for depression and
AUD are from specialist settings in high-income coun-
tries. The generalizability of these findings to LMICs is
compromised by several major contextual factors, such
as variations in the explanatory models of these disor-
ders, ways of coping and dealing with them, marked
variability in access to specialist services, and distinct
socio-economic determinants (such as literacy) [18,19].
There is a growing evidence base testifying to the effect-
iveness of approaches that address these challenges, not-
ably the systematic adaptation of PTs to suit the local
context and task-sharing their delivery to appropriately
trained and supervised lay and community health workers
in primary care and community settings [20]. There
is emerging evidence testifying to the cost-effectiveness
of task-sharing of PTs to non-specialist health workers
(NSHW) compared with enhanced usual care [21]. How-
ever, a recent systematic review observed that task-sharing
is associated with a number of barriers, primarily a lack
of resources [22], and generating further evidence on
its cost-effectiveness is a key strategy to address this
barrier. Identifying effective PTs delivered by NSHWs
was ranked amongst the leading research priorities for
global mental health in a recent systematic priority-setting
exercise [23].
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that seeks to develop and evaluate PTs for priority men-
tal disorders for delivery by NSHWs in routine health
care settings in India. The programme has systematically
developed PTs for moderate to severe depression and
HD and AD (Chowdhary et al., in preparation; Nadkarni
et al., in preparation). PREMIUM will now implement
two concurrent randomized controlled trials to evaluate
each of these treatments, delivered by the same NSHWs
(referred to as lay counsellors).
Objectives and hypotheses
The objectives of the two trials are to evaluate the effect-
iveness and cost-effectiveness of the Healthy Activity
Program (HAP), for adults with moderate to severe de-
pression, and the Counselling for Alcohol Problems
(CAP), for adults with HD or AD, delivered by the same
pool of lay counsellors in primary care in Goa, India.
The primary analysis group for the CAP trial are partici-
pants with HD. The primary hypotheses are that the PT
intervention in addition to enhanced usual care (EUC)
will be superior to EUC alone in reducing the severity of
symptoms and in increasing remission rates in partici-
pants with depression and HD at three months post-
enrolment. In addition, we hypothesize that the CAP will
reduce the physical, social, intrapersonal, impulsive and
interpersonal consequences of alcohol use at three
months in participants with HD. Secondary hypotheses
are that the PT intervention in addition to EUC will be
superior to EUC alone in reducing disability, suicidal be-
haviour and intimate partner violence, and that it will be
cost-effective from a health systems perspective. That is,
it would have a gain in quality-adjusted life years of no
more than the annual per capita gross domestic product
in India. Further to this, from a societal perspective, the
intervention will be dominant over EUC, with both a re-
duction in costs and superior outcomes.
We further hypothesize that the PT intervention will
increase activation (HAP trial) and uptake of detoxifica-
tion services (CAP trial). Table 1 provides a summary of
the trials outcomes.
Methods/design
Setting
The trials will be conducted in eight primary health cen-
tres (PHC) in the district of North Goa, a state on the
west coast of India. The publicly funded PHC is the first
port of call in India for people who wish to seek health
care in the public system.
Design
We will carry out a parallel arm randomised controlled
trial with equal allocation of participants between arms.Participants and procedures
The flow chart (Figure 1) shows the process of recruit-
ment and follow-up of participants in the trials. The
HAP trial will include participants of both genders, and
the CAP trial will only include male participants because
HD and AD are rare in women in India [24]. Eligible pa-
tients will be invited to participate in either the HAP or
CAP trial as appropriate by the health assistant after the
patient’s consultation session with the PHC doctor. After
provision of written and verbal information, consent will
be sought. A record of the age, educational attainment,
marital status, gender, screening questionnaire score and
reason for refusal will be maintained for those who do
not consent. Eligible patients who are willing to partici-
pate in the trial but are unable to complete the informed
consent procedure due to time constraints will be in-
vited to return on another occasion, or followed-up by
the health assistant at their homes or a convenient loca-
tion to complete the procedure. Such patients will be
allowed a period of two weeks to confirm their participa-
tion in the trials. Recruitment will be censored to a max-
imum of the first two to three eligible participants per day
(irrespective of the type of disorder) to ensure uniform stag-
gering across all PHCs (which vary in size of patient attend-
ance) and to avoid over-loading of counsellors.
Inclusion criteria
Eligible participants will be PHC attendees aged 18 to
65 years who are intending to reside at the same address in
the catchment area of the PHC for at least 12 months. This
age range was chosen because persons younger than
18 years require parental consent for participation in re-
search and our pilot study showed that those over the age
of 65 had particular difficulties in engaging with the PT.
Participants will be included if they screen positive on the
Patient Health Questionnaire-9 (PHQ-9) and/or the Alco-
hol Use Disorders Identification Test (AUDIT), and if they
give informed consent.
Exclusion criteria
Pregnant women, patients who need urgent medical
attention (defined as needing emergency treatment or
in-patient admission), patients who are unable to com-
municate clearly (for example, due to a speech or hear-
ing disability or inability to comprehend one of the
programme’s four languages: Konkani, Hindi, Marathi or
English), and patients who are intoxicated at the point of
assessing inclusion and exclusion criteria will not be eli-
gible. These criteria will be determined by trained health
assistants at the PHC.
Identification of the target mental health conditions
Trained health assistants will interview consecutive PHC
attendees at the out-patient department who meet the
Table 1 Primary and secondary outcomes of the PREMIUM trials
Outcome Source of data (see Table 5 for details on each measure) End-point Analysis group
Healthy Activity Program Counselling for Alcohol Problems
Severity of symptoms Beck depression inventory-II Time line follow back 3a and
12 months
Depressiona,
HDa, AD
Remission Patient health questionnaire Alcohol use disorders identification test 3a and
12 months
Depressiona,
HDa, AD
Consequences of alcohol
use
NA Short inventory of problems 3a and
12 months
HDa, AD
Disability levels WHO disability assessment schedule WHO disability assessment schedule 3 and
12 months
Depression,
HD, AD
Costs of illness Client service receipt inventory Client service receipt inventory Over 12 months Depression,
HD, AD
Suicidal behaviour Patient Health Questionnaire-9 and a
dditional questions on suicide attempts
Patient Health Questionnaire-9 and
additional questions on suicide attempts
3 and
12 months
Depression,
HD, AD
Experience of intimate
partner violence
Questionnaire on intimate partner violence Questionnaire on intimate partner
violence
3 and
12 months
Depression
Level of behavioural
activation
Adapted version of the behavioural activation
for depression scale - short form
- 3 and
12 months
Depression
Uptake of detoxification
services
NA Client service receipt inventory 3 and
12 months
AD
aPrimary hypotheses. AD, alcohol dependence; HD, harmful drinking; NA, not applicable.
Assessed for eligibility for screening
N=
Females
Eligible for screening
Total screened PHQ-9 
Excluded
(reasons)
PHQ-9 score 15+
Refused
(reasons)
AUDIT score <12
PHQ-9 score 15+
Refused
(reasons)
PHQ-9<15
Eligible - consultation with PHC  
Declined to 
participate
AUDIT score <12
PHQ-9 score <15
AUDIT score 12+
Any PHQ-9 score 
Males
Eligible for screening
Total screened AUDIT+PHQ-9 
Eligible - consultation with PHC doctor 
Declined to 
participate
Allocated to CAP+EUC Allocated to EUC
3-month FU
Randomized
12-month FU
3-month FU
Informed consent
12-month FU
Allocated to HAP+EUC Allocated to EUC
3-month FU
Randomized
12-month FU
3-month FU
Informed consent
12-month FU
Figure 1 PREMIUM trials flow chart. AUDIT, Alcohol Use Disorders Identification Test; Counselling for Alcohol Problems; HAP, Healthy Activity
Program; PHQ-9, Patient Health Questionnaire-9; PHC, Primary Health Clinic; FU, Follow Up.
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PHQ-9, a nine-item questionnaire that has previously
been validated for use in the study setting [25]; the cut-
point of 14 selected is the most accurate for detection of
moderate to severe depression [26] and has a high posi-
tive predictive value for depressive disorder defined by
the International Classification of Diseases revision 10
[27]. To detect HD or AD, they will use the AUDIT, a
10-item screening questionnaire for AUD, developed by
the WHO [28]. The AUDIT has been validated and used
in cross-national studies, including in India [29], and has
been field-tested in the study setting [30]. The AUDIT
allows for varying the cut-off score depending on the
country’s drinking patterns, the alcohol content of stand-
ard drinks, and the nature of the screening program. For
the purpose of this study the threshold score will be 12.
The AUDIT has been adapted to cover a three-month
period to be consistent with the three-month outcome
assessment, as in other studies [31].
The order of assessments for male patients will be the
AUDIT first, followed by the PHQ-9; those who screen
positive for both disorders will be invited to participate
in the CAP trial, following the guidelines for the treat-
ment of co-morbid depression and HD and AD [32]. Pa-
tients who screen negative and re-enter the PHC will
not be offered the opportunity for re-screening until
three months after their initial screening.
Baseline assessments
After consent has been obtained, the health assistant will
collect the following data on potential moderators of
treatment effect: age group, gender, marital status, em-
ployment status [33], duration of the illness [33] (for
HAP), readiness to change drinking behaviour [34] (for
CAP), severity of depression or drinking [35], and the
patient’s expectations in the effectiveness of PTs for their
health problem [36]. All assessments will be audio-taped
(with permission), and the tapes randomly selected for
review by the supervisor for quality assurance.
Randomization
Randomization will be carried out after completion of
the baseline assessments. The randomization list will be
generated by a statistician independent of the trial. The
list will be stratified by PHC and sex (for the HAP trial)
using randomly sized blocks of four to six (two to four
for men in the HAP trial). The randomization code will
be concealed using sequentially numbered opaque sealed
envelopes to maximise allocation concealment [37]. The
envelopes will be prepared at the London School of
Hygiene and Tropical Medicine (LSHTM) by personnel
independent of the trial and shipped to the data man-
ager at the trial site. We will ensure fidelity of treatment al-
location is not compromised by using differently colouredenvelopes for the two trials, each of which will have a
sticker with clinic number, gender (for HAP) and trial ID
number. The envelopes will be taped down for extra se-
curity. Inside will be a plain piece of card folded in two,
and inside the card will be a sticker with the ID number
and allocation. A daily check by the data manager will be
performed to evaluate if allocations done are consistent
with the allocation code.
Sample size estimation
The sample size estimations are made on the following
assumptions: patients are randomized within each of the
eight clinics; one counsellor per PHC; an intra-cluster
correlation of 0.04 (this is based on the MANAS trial [6]
and may be conservative, as the CoBalT trial found within-
therapist clustering of only 0.0027 [5]); a loss to follow-up
of 15% over three months (conservative, based on the
MANAS trial in Goa, which was 13% over six months [6]);
and equally sized groups (1:1 allocation ratio).
Based on these assumptions, we aim to recruit 500 par-
ticipants with depression for the HAP trial and 600 partic-
ipants with HD or AD for the CAP trial, to yield the
required sample size of 400 patients with HD (AUDIT
scores of 12 to 19; those who score > 19 are categorized as
AD). The power we will have to detect effect sizes for the
outcomes for analyses of primary and secondary analysis
groups are specified in Tables 2, 3 and 4.
The PREMIUM interventions
The psychological treatments
The PTs were developed in a systematic process that
built upon the experiences of the investigators in adapting
mental health interventions for use in under-resourced
and socio-culturally diverse contexts [43-50]. The key
principles of this approach were to dismantle evidence-
based PTs and combine them with strategies identified as
being useful in the local context. Evidence-based PTs were
identified based on the WHO Mental Health Gap Action
Programme (mhGAP) guidelines for use in primary care
[4]. Contextually appropriate strategies were identified
through a review of explanatory models, PT studies and
qualitative studies with persons with the target disorders,
their care-givers and health care providers (including al-
ternative and religious healers) about key outcomes and
coping strategies. The strategies were collated and the list
reduced by merging those that were similar. Strategies
that were rated by local mental health providers and
NSHWs as being acceptable, safe and feasible for delivery
by NSHWs in primary care were taken to the next stage
of synthesis into a formal PT in intervention development
workshops. This process led to the identification of behav-
ioural activation and motivational enhancement therapy
as the theoretical framework for the emerging PTs for
depression and HD or AD respectively. The next phase of
Table 2 Power calculations for the Healthy Activity Program trial
Outcome Total sample
size
Number
per arm
Number of
clinics
Treatment
arm
Enhanced usual
care arm
SD Effect
size
Power
BDI-II mean score (primary) 500 250 8 16.8 17.9a 2.8a 0.4c 86%
500 250 8 16.65 17.9a 2.8a 0.45c 93%
500 250 8 16.5 17.9a 2.8a 0.5c 97%
500 250 8 18.9 24.5b 10.7b 0.5 98%
Remission (PHQ-9 < 10) (primary) 500 250 8 62% 44%d - - 81%
500 250 8 65% 44%d - - 92%
WHO DAS mean score (secondary) 500 250 8 15.0 17.0e 5.0e 0.4 87%
500 250 8 14.5 17.0e 5.0e 0.5 97%
aBased on pilot PREMIUM data, where BDI score was 17.9 with SD 2.8. bBased on the COBALT trial [5]. The mean BDI-II score at six months was 24.5 (SD 13.1) in
the usual care arm and 18.9 (SD 14.2) in the intervention arm (among participants with a BDI > 14 at baseline). The study reported an effect size of 0.53, based on
the pooled SD of baseline BDI-II score (SD = 10.7). cEffect size of 0.4 to 0.5 is based on the recent meta-analyses of behavioural therapy for depression, which found
a summary effect size of 0.42 for depressive symptoms based on low intensity interventions (internet-based or guided interventions with limited support by a
health professional) [38] and of 0.7 (95% CI: 0.39, 1.00) for all behavioural interventions [39]. Two further trials found effect sizes of 0.53 [5] for a cognitive
behavioural therapy-intervention on BDI score and 0.76 [40] for behavioural activation on BDI score. dProportion recovered from any common mental disorder
among baseline depression cases in MANAS in the enhanced usual care arm at three months. eBased on 12-month WHO-DAS scores among those who had
moderate or severe common mental disorders at baseline in the MANAS trial. BDI, Beck’s Depression Inventory; PHQ-9, Patient Health Questionnaire-9; WHO DAS,
World Health Organization Disability Assessment Schedule.
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adaptation of PT manuals based on the source behavioural
activation manual [51] and motivational enhancement
therapy manual [52], and by testing the delivery of the PTs
to patients with the target disorders both by specialists
and lay counsellors. The PTs were finally subjected to a
pilot study in which lay counsellors delivered them to
patients in PHCs; modifications were made at this stage to
enhance acceptability, feasibility and scalability, notably
through the inclusion of home-based delivery, use of
pictorial patient resource materials, strategies to encour-
age the involvement of a significant other in the treatment,
and task-sharing the supervision of lay counsellors to peer-
groups. In addition, a generic counselling skills manual
was used to train counsellors in core skills required for the
delivery of both PTs. These manuals of the treatments are
available on a database on the Sangath website [53].
The resulting PT for depression is the HAP. HAP
comprises up to eight sessions delivered in three flexible
phases over two to three months with each session last-
ing between 30 and 45 minutes. The optimal number ofTable 3 Power calculations for the Counselling for Alcohol Pr
Outcome Total sample
size
Number
per arm
Mean standard ethanol content consumed
in past two weeks
400 200
400 200
400 200
AUDIT score < 8 at 12 months 400 200
400 200
aBased on the effect size in the meta-analysis by Vasilaki et al. which found an effec
treatment in reducing alcohol consumption among non-dependent drinkers [41]. bB
abstinence rates of 68% versus 40% two months after randomisation [42].sessions for HAP are five or six, at which point the pilot
study showed the largest reduction in depression scores;
however, a few patients needed up to eight sessions to
achieve this outcome. Patients are encouraged to complete
the first session on the day of recruitment; those unable to
complete a full session are offered an abbreviated session.
The core strategies of HAP are behavioural assessment
and self-monitoring, psychoeducation about the relation-
ship between activity and mood, activity structuring and
scheduling, and problem-solving. The CAP uses content
derived from motivational interviewing along with other
behavioural and cognitive components. CAP has three
phases, and is delivered flexibly over one to four sessions
(30 to 45 minutes each) over six to eight weeks. The opti-
mal number of sessions is two, with a maximum of four
sessions for the small proportion of patients who are either
at the more severe end of the spectrum or do not achieve
treatment goals. The core strategies of CAP are detailed
assessment, personalised feedback, evoking commitment
to change and development of a change plan, drink refusal
skills, managing drinking urges, management of emotions,oblems trial
Number of
clinics
Treatment
arm
Enhanced usual
care arm
Effect
size
Power
8 0.4a 82%
8 0.45 93%
8 0.5 97%
8 60% 40%b - 84%
8 68% 40%b - 99%
t size of 0.4 (95% CI: 0.36, 0.44) for Motivational Interviewing versus no
ased on the randomized controlled trial by Bager et al., which found
Table 4 Power calculations for the Counselling for
Alcohol Problems trial on available sample sizes for
sub-group analyses
Sub-group Outcome Sample
size
Power Effect
size
Harmful drinking
and alcohol
dependence
Mean standard ethanol
content consumed in past
two weeks
638 0.50 99%
0.40 92%
0.33 80%
0.40 63%
0.33 48%
Alcohol
dependence
Mean standard ethanol
content consumed in past
two weeks
238 0.50 86%
0.40 69%
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patients with AD will receive a structured referral to de-
toxification services.
Both PTs will be delivered on an individual basis either
at the PHC, the patient’s home or a convenient place
suggested by the patient, or on the telephone. Any par-
ticipant receiving the maximum number of stipulated ses-
sions of the PT or completing treatment goals in fewer
sessions will be discharged. Participants receiving HAP
who do not respond to the PT at the end of eight sessions
will receive a referral to psychiatric services. Any partici-
pants missing three consecutive scheduled sessions will be
considered as a treatment drop-out. However, participants
who re-engage at any point during the trial will be offered
the opportunity to continue from the last session.Counsellors The PTs will be delivered by lay counsellors
who are members of the local community, are above
18 years of age, have completed at least high school edu-
cation, do not have professional mental health training,
and have an expressed desire to help people with mental
health problems. Trainee counsellors were recruited by
placing advertisements in newspapers and through word
of mouth, and selected based on their performance in a
structured interview and role play. Post selection, the
trainees underwent a three-week participatory workshop
covering both PTs. Trainees who met competency stan-
dards (based on role play and multiple choice questions)
progressed to the pilot study. Training was conducted
by five local specialists who were previously trained by
international experts and continued to receive once
monthly supervision via Skype. In the pilot study the
trainee counsellors delivered the PT to eligible patients
in PHCs. Supervision was carried out both in individual
and weekly group format by the local specialists. Therapyquality was assessed mainly through rating of audio-taped
sessions using a specially developed scale, the Quality of
HAP and Quality of CAP adapted from the Counselling
Skills Scale [54], the Quality of Behavioural Activation
Scale (Dimidjian S, Hubley A, Martell CR, Herman-Dunn
R, Dobson KS: Quality of behavioral activation scale
(Q-BAS): Unpublished) and the Motivational Interview-
ing Target Scheme [55]. As the trainee counsellors gained
experience in delivering the intervention, the supervision
format evolved from expert led (that is, local mental
health professionals skilled in the delivery of the PT) to
peer-led group supervision. Only trainees who achieved
competence, as assessed by standardised role plays and
therapy quality assessments, were selected to deliver the
PTs in the trials. Each PHC will have one counsellor, with
a pool of back-up counsellors in the event of counsellors
leaving or if weekly load of patients exceeds counsellor
limit.Supervision Supervision during the trial will be primar-
ily in a peer-led group format with supervision groups
held once a week in the field office or a PHC. Supervi-
sion will comprise two types of activities: first, assess-
ment of the quality of sessions (using the quality rating
scales) based on selected audio-recordings of sessions
and, provision of peer feedback; and second, discussion
of any difficult cases. If treatment-related issues cannot be
resolved in the peer group they will be discussed with ex-
perts. In addition, individual supervision will take place
twice a month on-site (that is, at the respective PHC) by
an expert who will review individual patient progress and
quality of documentation, assess any patient safety issues,
and address any site- or counsellor-specific practical diffi-
culties or concerns.Enhanced usual care
Usual care in primary care for depression and HD or
AD in India is, in effect, no care at all. This has been
confirmed in the study setting during the pilot study.
This is primarily because most cases are not diagnosed
and, amongst those who are, most do not receive ei-
ther antidepressants or PT. In the PREMIUM trials,
usual care will be enhanced by providing the screening
results to the primary care physician; providing a contex-
tualized version of the mhGAP guidelines [4] for the
target disorders to the primary care physician, includ-
ing guidelines on when and where to refer patients
for psychiatric care.
This EUC is the most intensive model of primary care
for both target disorders that may be envisaged in the fore-
seeable future in India or other LMICs, and is the one that
is currently recommended by the WHO’s mhGAP [56].
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Contamination of the EUC arm will be minimized by
masking the PHC doctor to the allocation status of the
patient and not offering formal training in the PTs to
any of the PHC staff. If there are any clinical issues aris-
ing from the counselling that need PHC doctor involve-
ment, the counsellor will advise the patient to speak to
the doctor about this, or will consult the expert super-
visor for guidance.
Outcome evaluation
Outcome data will be collected at three months and
12 months post-enrolment. The three-month outcome is
the primary end-point for both trials as the PTs delivery
will be completed and we would expect the optimal ef-
fect of the treatment. The 12-month end-point is in-
cluded to evaluate the sustainability of the effect of the
intervention. The outcome assessment measures with
the specific outcomes for each trial are summarized in
Table 5. The primary outcome measures for the HAP
trial are the Beck’s Depression Inventory and the PHQ-9,
and for the CAP trial, the Time Line Follow Back, the
Short Inventory of Problems and the AUDIT. The add-
itional costs of delivering PTs and EUC, impacts on the
use of health care services, lost time from everyday usual
activities including paid work, as well as time and mon-
etary costs to families will be assessed using data col-
lected with a tailored version of the Client Service Receipt
Inventory.
Masking of outcome assessments
Baseline assessments will be carried out by the health as-
sistants in the PHC before randomization. The three-
and 12-month outcome assessments will be carried out
by an independent team of field workers who have no
contact with the PHCs and who will be entirely commu-
nity based (that is, assessments will be done at home, to
minimize the risk of unmasking). The intervention and
outcome evaluation teams will not have any interactions
during the trial and will maintain separate physical loca-
tion and administrative management. The evaluators and
participants will be told that we are evaluating two differ-
ent interventions and that there is clinical equipoise about
whether one is better than the other. Primary outcome
measures will be completed at the first contact, reducing
the likelihood of it being affected by unmasking during
the assessment.
Fidelity assessments
Two types of indicators will be collated to evaluate the fi-
delity of the delivery of the PTs, namely, their quantity and
quality. Quantity indicators collated through counsellor
case records will measure the number, mode of delivery
(that is, home, PHC, telephone), and duration of PTsessions. Quality indicators will be assessed through rat-
ings of 10% of audio-recording transcripts of all sessions
by independent experts blind to outcome data using the
respective PT quality assessment scales.
Nested qualitative study
The aim of the qualitative study is to explore patient
perceptions of the quality of the care received and any
beneficial or adverse effects, satisfaction with care, and
the impact of their health problems on their daily lives,
economic productivity and lives of family members. Par-
ticipants will be purposively recruited after completing
the 12-month outcome assessments by the independent
statistician (to maintain blinding) to ensure balance of
arms, recovery status and PHCs. We expect to carry out
in-depth interviews with up to 40 participants from each
trial, within one to two weeks of completion of the
secondary end-point quantitative assessments. In-depth
interviews will be conducted until data saturation is
reached. All interviews will be audio-taped. Subsequently,
the memos (reflective notes about the interviews) and field
notes written by the interviewers will be attached to the
main text of the interviews. The qualitative researchers
will be separate from the quantitative outcome assessment
team.
Data management
Three types of quantitative data will be collected: base-
line, intervention process and outcome assessment. All
baseline and outcome data (with the exception of a part
of the Client Service Receipt Inventory) will be captured
electronically using tablet computers, as will process
data from lay counsellors. The data will be remotely
uploaded as comma separated values (CSV) files on the
main data server running online using the customized
STAR software program [70], which is compliant with
Good Clinical Practice (including a date- and time-stamp
for original data entry, and an audit trail documenting any
subsequent changes). PT process data and therapy quality
data will be collected in paper form; these will be manually
entered and stored as CSV files using the same data col-
lection platform used for the electronic data. Range and
consistency checks will be performed at weekly intervals
separately for each data source. Queries identified will be
resolved promptly by the trial management team, and the
database updated, maintaining the audit trail. All data will
be kept in separate databases and only merged into a mas-
ter database after data collection is completed and each
individual database is locked. All data is backed-up on
external hard disks on a daily basis. Access to pre-locked
data will be password-protected at multiple levels and
no member of the trial team apart from the data
manager and independent statistician will have access
to these passwords. After the dataset is locked, it will
Table 5 PREMIUM outcome assessments
Instrument Trial Description Outcome Contextual validity
Beck Depression
Inventory-II
HAP 21-item questionnaire assessment of depressive
symptoms assessed on a scale of 0 to 3.
Mean total score Widely used measure for evaluating
depression in trials, including in
India [57,58].
Time Line Follow
Back
CAP Calendar tool supplemented by memory aids to
obtain retrospective estimates of daily drinking
over a specified time period.
Alcohol consumed in
past two weeks (g)
Validated instrument [59] used in
India [60].
AUDIT CAP 10-item questionnaire with three questions on
the amount and frequency of drinking, three
questions on alcohol dependence and four on
problems caused by alcohol.
Mean AUDIT score Validated with primary health care
patients in six countries [28] and
used in study setting [61].
Remission
(AUDIT score < 8)
Short Inventory of
Problems
CAP 15-item questionnaire which assesses physical,
social, intrapersonal, impulsive and interpersonal
consequences of alcohol consumption.
Adverse consequences
of alcohol consumption
Validated instrument [62] and used in
India [63]. Translated into Konkani
using standardized procedure
followed by piloting.
PHQ-9 HAP
CAP
Nine-item questionnaire assessment of depressive
symptoms assessed on a scale of 0 to 3.
Prevalence of moderate-
severe depression; mean
total score.
Validated in primary care and
Konkani version validated in Goa
[25].
WHO Disability
Assessment Schedule
HAP
CAP
12-item questionnaire for measuring functional
impairment over the previous 30 days. In
addition, two items assess number of days the
person was unable to work in the previous
30 days.
Total disability score;
quality adjusted life
years; number of days
out of work.
Validated for international use [64]
and used in previous trials in Goa
[6,65].
Client Service Receipt
Inventory
HAP
CAP
Questionnaire to collect data on the utilization
and costs of health care and lost productivity
(including that of care-givers).
Costs of illness (direct
and indirect)
Previously used in trials in the study
setting [66,67] and elsewhere in
India [65,21].
Violence and suicidal
behaviour
HAP
CAP
Item 9 of the PHQ-9 with additional questions
on suicide attempts and IPV.
Suicide plans and
attempts
Based on interviews used in earlier
studies in Goa [68].
Experience of IPV
(for HAP trial only)
Perpetration of IPV
(for CAP trial only)
Abbreviated Behavioural
Activation for Depression
Scale - short form
HAP Adapted version of the Behavioural Activation
for Depression Scale - short form [69].
Indicators of behavioural
activation
Translated into Konkani using
standardized procedure followed by
piloting.
AUDIT, Alcohol Use Disorders Identification Test; CAP, Counselling for Alcohol Problems; HAP, Healthy Activity Program; IPV, intimate partner violence, PHQ-9,
Patient Health Questionnaire-9.
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have access to the datasets. Qualitative data will be
collected using digital recorders together with written
field notes and memos. The former will be tran-
scribed in the language of the interview, anonymized
but linked with the trial ID and then translated for
analysis. A similar procedure will be followed for the
written data. Digital recordings will be stored in a se-
cure, password-protected folder. For all data, a separ-
ate file linking names and trial IDs will be kept and
password-protected.
Analysis
Quantitative analyses will be carried out using Stata
(version 13). Below is a summary of our approach to
the analysis. A detailed analysis plan will be agreedwith the Data Safety and Monitoring Committee towards
the end of the trial and before any analysis is undertaken.
Descriptive analyses
Initial analyses will compare baseline characteristics of
individuals who consented and did not consent, and par-
ticipants who did and did not complete outcome assess-
ments respectively. Baseline characteristics of enrolled
participants will be compared between treatment arms.
Findings will be reported as per the CONSORT guide-
lines [71], including a trial flow chart. This will include
total adult PHC attendees within period of screening,
total assessed for inclusion and exclusion criteria, num-
ber of patients meeting inclusion or exclusion criteria,
number screened for eligibility, number consenting to
enter the trials, and number refusing or excluded (with
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tively withdrawing, and passively lost to follow-up will
be shown by arm. The outcome measures will be sum-
marised at recruitment, at three-month and 12-month
follow-up by intervention arm, and overall. These will
be summarised by means (standard deviation), medians
(interquartile range), or numbers and proportions as
appropriate by key relevant subgroups (such as age,
gender and baseline outcome score). For continuous
outcomes, histograms will also be plotted within each
arm to assess normality and whether any transform-
ation is required.
Outcome analyses
The primary analyses will be intention-to-treat at the
three-month end-points adjusted for baseline values
(where assessed), regardless of adherence to the PT. The
size of the trial and the randomization design should
ensure balance between arms. However, this will be
checked and adjustments included for any a priori
defined potential confounding variables for which
randomization did not achieve reasonable balance be-
tween the two arms at baseline. PHC will be adjusted for
as a fixed effect in the analysis to allow for within-PHC
clustering. There will usually be only one counsellor per
PHC so we will not additionally adjust for counsellor vari-
ation. Analyses of outcome will be conducted using logis-
tic regression for binary outcomes (for example,
percentage with depression, percentage with HD), and
linear regression for continuous outcomes (for example,
depression scores). Effect sizes will be reported as crude
and adjusted relative risks estimated using the marginal
standardization technique with 95% confidence intervals
for the ratios estimated via the delta method [72] for bin-
ary outcomes; and mean differences and standardised
mean differences with 95% confidence intervals for con-
tinuous outcomes. Missing outcome data will be imputed
using multiple imputation, implemented in Stata [73].
Given that we have only two follow-up time points
(three and 12 months), the analyses will be conducted
and interpreted separately for each of these time points.
No interim analyses of outcomes are planned.
Moderator analyses
A moderator analysis will be conducted to help clarify
for whom and under what circumstances (moderators)
each of the PT treatments work. We will assess modifi-
cation of treatment effect by a priori defined modifiers
(age group, gender, marital status, employment status,
chronicity of illness (for depression), readiness to change
drinking (for HD or AD) severity of depression or drink-
ing, and patient expectations), by fitting relevant inter-
action terms and testing for heterogeneity of treatment
effects in regression models.Compliance analysis
As we expect a proportion of our participants to have
poor compliance to the PTs, we will undertake Complier’s
Average Causal Effect analyses, which estimates the effect
of the PT on the participants who received it in full as
intended by the original randomization [74].
Economic evaluation
Cost-effectiveness analysis and cost utility analysis will be
conducted assessing the incremental cost-effectiveness of
PT versus EUC in both trials. The cost-effectiveness ana-
lysis will make use of the primary clinical outcome data
collected in the trials, while quality of life impacts esti-
mated by transforming data collected using the WHO
Disability Assessment Schedule will be used for cost utility
analysis. The economic analysis will be conducted from
both a health system perspective and a wider perspective
incorporating societal impacts that include costs to fam-
ilies and impacts on economic productivity. The costs of
the PTs will be estimated by deriving a monetary value for
each component of the treatment based on actual time
and resources required for delivery and costs incurred,
and applying these to each individual based on the process
indicators that reflect the actual uptake of the treatment.
Other health care, patient- or family-borne resource use
and costs, including any informal caregiver time costs,
and productivity losses will be computed and compared
at three and 12 months, and subsequently related to
changes in health outcome. In the event that dominance
is not shown, that is, the PT is more effective but the costs
are also more than the EUC group, incremental cost-
effectiveness ratios will be computed, together with their
confidence intervals (using bootstrapping techniques to
overcome expected skewness of cost data). Cost-
effectiveness acceptability curves will also be derived
in order to show the probability of any cost-effective
advantages for the PTs at a range of 'willingness to
pay' threshold levels, for both the health system and
the broader societal perspectives.
Qualitative study analysis
Thematic analysis will be carried out using appropriate
software. Two researchers will first read and familiarize
themselves with the data. Then they will select 10 inter-
views and inductively generate initial codes through
reading the interview transcript. Based on the coded
data and the original research questions, the codes will
be defined and collated into potential themes, and the
code book refined. Inter-rater reliability will be tested by
double-coding 10 randomly selected interview tran-
scripts and the code book finalized. The researchers will
then code the entire dataset. Vivid and compelling ex-
amples of narrative extracts will be selected, analysed
and related to the research questions. Deviant case
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consistent with the themes.
Ethical considerations
The trial protocol has been granted ethical approval from
the Sangath and LSHTM Institutional Review Boards.
The LSHTM is the trial sponsor. Written (or witnessed,
if the participant is illiterate) informed consent will be
mandatory for enrolment. All consent procedures will be
audio-taped, with the patient’s approval, for quality assur-
ance. Separate consent will be taken for participation in
the qualitative study. All participants will be able to access
EUC, which represents a higher quality of care than what
is currently available and is consistent with the type of
care currently envisaged in India's District Mental Health
Program. We will protect the confidentiality of personal
data principally through procedures to separate study data
and participant identifiable data. Quantitative data gath-
ered in the tablets for each participant at baseline will
retain personal identification items to minimize errors
in transcribing identities, but these will be removed be-
fore transferring the data to Stata for analysis. We will
monitor the occurrence of three specific serious adverse
events (SAEs) - death, suicide attempt, and unplanned
hospitalization from any cause, will be recorded at three-
and 12-month outcome assessments. Their reporting and
appropriate responses will be governed by the standard
operating procedure approved by the Data Safety and
Monitoring Committee, which sets out the a priori criteriaTable 6 Trial management committees
Committee Role
Trial
Management
Committee
(TMC)
To monitor all aspects of the conduct and progress of the
ensure that the protocol is adhered to and take appropria
to safeguard participants and the quality of the trial itself.
Trial Steering
Committee (TSC)
To provide overall supervision of the trial and ensure that
conducted in accordance with the protocol and the relev
regulations. The TSC should approve the trial protocol and
protocol amendments and provide advice to the TMC on
of the trial. Decisions about continuation or termination o
or substantial amendments to the protocol are finally the
responsibility of the TSC.
Data Safety
Monitoring
Committee
(DSMC)
The DSMC will review the accruing trial serious adverse ev
reports to assess whether there are any safety issues that
brought to participants’ attention or any reasons for the t
continue. It is the only body that makes recommendation
unblind data and makes further recommendations to thefor unblinding of adverse events (that is, a statistically sig-
nificant difference in prevalence between the two arms at
P <0.01). SAEs will be compiled by the data manager at
the end of the week during outcome follow-ups, and the
report shared with the principal investigator and a psych-
iatrist independent of the trials. The independent psych-
iatrist will make contact with the respondent within
24 hours of receiving the SAE report, to arrange a con-
venient time and place to complete a detailed interview ei-
ther on phone or face to face and offer any necessary
intervention. A blinded summary of SAEs will be sent to
the Data Safety Monitoring Committee and Institutional
Review Boards on a quarterly frequency. Patients in the
HAP trial who remain symptomatic at the end of the trial
will be offered free specialist care services from the inde-
pendent psychiatrist.
Trial management
Three committees will monitor the progress of the trial
(Table 6). Trial monitoring will comprise the collation and
reporting of routine trial process indicators and adverse
events. Summary statistics and graphs showing trends over
time will be compiled for the process indicators, and re-
ported on a weekly basis to the Trial Management Com-
mittee and monthly to all members of the Trial Steering
Committee. The Data Safety and Monitoring Committee
will receive three-monthly reports of SAEs, the trial flow
charts, and tables showing baseline comparability of pa-
tient characteristics between arms.Members Frequency
of meeting
trial,
te action
• Principal investigator Weekly
• Trial manager
• Intervention team leaders
• Outcome evaluation coordinator
• Project coordinator
• Data manager
it is being
ant
any
all aspects
f the trial
• Independent chairperson (Lakshmi Vijayakumar,
a psychiatrist and trialist from Chennai)
Six-monthly
• Co-investigators (Betty Kirkwood, Christopher
G Fairburn, Helen Weiss and Michael King)
• Members of the TMC
ent
should be
rial not to
s to
TSC.
• Sunita Bandewar (anthropologist with
expertise in research ethics),
Six-monthly
• Soumitra Pathare (psychiatrist with expertise in
mental health law and human rights, member
of national Mental Health Policy Group)
• Paulomi Sudhir (clinical psychologist)
• Nikhil Gupte (biostatistician, runs a clinical
trials unit)
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The PREMIUM trials will extend evidence on the effect-
iveness of PTs when delivered by NSHWs in LMIC con-
texts [20]. The trials, which address two leading causes
of the mental health-related global burden of disease, are
designed to be used in routine primary health care set-
tings, employing minimum exclusion criteria for participa-
tion, using the same pool of affordable and available
human resources, and include a comprehensive economic
assessment. These factors all point to the potential scal-
ability of the findings. The main limitation of our trial
design is that we are not using diagnostic interviews to
characterize our participants or the outcomes; however,
these are not practical in the context of the trial and not
generalizable in the real-world of primary health care. The
delivery agent of the PTs is not a routine health care
worker but a counsellor specifically employed by the
programme, and thus the trial findings will need to be
interpreted cautiously in terms of their scalability. Finally,
while we have argued for the rationale of using the same
pool of counsellors to deliver both PTs, there is an obvious
risk that this design may reduce their effectiveness in
delivering each PT with optimal quality and fidelity.
Ultimately, we anticipate that the long-term impact of
the evidence generated by PREMIUM will be to con-
tribute to closing the treatment gap for mental disorders
in low-resourced settings through scaling-up effective PTs
for delivery by NSHWs by offering a range of practical
tools (such as treatment manuals, patient resource mate-
rials and quality assessment tools) to complement the
WHO’s mhGAP guidelines. In doing so, new treatments
will be developed with potential applicability not only in
LMICs but in well-resourced contexts as well, as the
human resource costs of mental health care spiral in
all countries.
Trials status
Enrolment for the trials begun on 28 October 2013.
Based on our experiences with the pilot study, we ex-
pect approximately 4% prevalence of depression and
HD (based on screening over 14,000 adult PHC at-
tendees) and a 50% participation rate. Thus, with eight
PHCs, each enrolling three participants per week for ei-
ther trial, we expect to complete recruitment of our target
samples in 12 months (that is, by the end of October
2014) and complete the primary end-point three-month
outcome evaluation by the end of January 2015. The final
12-month outcome evaluation will be completed by the
end of October 2015. In the event that one trial attains the
expected sample size ahead of the other, recruitment will
still continue till the other trial achieves its target. This is
to ensure consistency in trial design and that counsellors
are able to see similar groups of patients so that they do
not behave differently.Abbreviations
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